New hope for kids with Ultra-Rare, aggressive cancers
NCT ID NCT04416568
Summary
This study is testing whether a combination of two immunotherapy drugs (nivolumab and ipilimumab) can help control rare, aggressive cancers in children and young adults. The trial is for patients whose cancers have returned or haven't responded to standard treatments. Researchers want to see if this drug combination can shrink tumors and extend survival for these difficult-to-treat conditions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATYPICAL TERATOID/RHABDOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Boston Children's Hospital
Boston, Massachusetts, 02115, United States
-
Children's Healthcare of Atlanta-Egleston
Atlanta, Georgia, 30322, United States
-
Children's Healthcare of Atlanta-Scottish Rite
Atlanta, Georgia, 30342, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States
-
UCSF Benioff Children's Hospital
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.